Peter Wehrwein

FDA Commissioner Stephen Hahn and CBER Director Peter Marks also fielded questions about pregnant women, teenagers and one dose versus two.

The five states have moved to prohibit accumulators and maximizers as the federal government takes a hands-off approach, according to John “Jack” S. Linehan, a lawyer at Epstein Becker Green, who is featured in this second part of a two-part video series.

The FDA's first emergency OK of a COVID-19 vaccine is expected to be followed next week by a second one for Moderna's vaccine.

John “Jack” S. Linehan, a lawyer at Epstein Becker Green, is featured in the first part of a two-part video series on copay accumulators and maximizers.

MHE's Peter Wehrwein speaks with Kevin Lewis, president and CEO of Community Health Options in Maine. The two discussed how Community Health Options is improving patient access through telehealth and more services on Tuning Into The C-Suite's newest series MHE Talks: Improving Patient Access.

Biden is also ready to announce that MGH infectious disease chief Rochelle Walensky is his pick for top job at the CDC

New Mexico Gov. Michelle Lujan Grisham and former Surgeon General Vivek Murthy appear to be the frontrunners for HHS secretary in the Biden administration.

Therapies that target lung cancer at the molecular level are proliferating — and so are the biomarkers for guiding their use.

Leanne Berge, CEO of Community Health Plan of Washington in Seattle, talks to Managed Healthcare Executive about patient access challenges, COVID-19, telehealth, and health care disparities.

This week on Tuning into the C-Suite, listeners are tuning into the next feature of the Meet the Board Series where Managed Healthcare Executive Senior Editor Peter Wehrwein and Associate Editor Briana Contreras speak with MHE’s Board Member Kevin Ronneberg, M.D. Kevin is vice president and associate medical director for health initiatives at HealthPartners, an integrated, nonprofit provider and health insurance company located in Bloomington, Minnesota. During the conversation we got to learn more about Kevin, personally, and how he and his family are doing during the pandemic and his thoughts of the current issues healthcare is facing today.

Entresto (sacubitril-valsartan) didn’t get a lot of love from payers after it was approved in 2015 because of its expense and the crowded armamentarium for heart failure. But Entresto has since made its way into guidelines for reduced ejection fraction heart failure, sometimes called systolic heart failure.

Some employers would benefit if their older employees go on Medicare, and people in their 60s would have some safety net if they can't find a job with benefits. Provider revenues might take a hit because of lower Medicare reimbursement.

Overall, the Polycap polypill (simvastatin, atenolol, hydrochlorothiazide, ramipril) falls well short of the high expectations for the polypill approach to cardiovascular disease risk reduction.

John Henderson, president and CEO of the Texas Organization of Rural and Community Hospitals, spoke with Senior Editor Peter Wehrwein about COVID-19, telehealth, emergency care, and Medicaid expansion.

In this second of a two-part video interview with MHE, Amwell Chief Medical Officer Peter Antall says he is in favor of extending CMS waivers that made telehealth visits reimbursable and easy for patients and providers.

Some safe predictions for healthcare under the Biden administration: More deference to public health officials on COVID-19 and efforts to create a public option and have Medicare negotiate drug prices.

In this first of two-part video interview with MHE, Amwell Chief Medical Officer Peter Antall says the Boston-based telehealth company typically white labels its software to a client’s brand.

RAND study puts some numbers to telehealth surge but also shows evidence of disparities along income, racial/ethnic lines.

Open enrollment has started and the median premium increase is 1.1%, according to the Kaiser Family Foundation.

The Johns Hopkins professor and new MHE editorial advisory board member discusses screening among race, how certain screening tests intensify health disparities and how the Trump administration is not correctly applying science within healthcare in this final part of a four-part video series.

Pfizer, the reputed leader in the COVID-19 vaccine race, may not have efficacy results for awhile. Meanwhile, AstraZeneca and Johnson & Johnson have resuming enrolling volunteers in the U.S. in their late-stage trials.

“Lung cancer screening is a great example of the problem,” says the former chief medical and scientific officer for the American Cancer Society in this third of four-part video series.

Rather than stopping hydroxychloroquine altogether, doses could be reduced and patients monitored if there are signs of retinopathy, say the authors of a commentary in the American Journal of Ophthalmology.

Pfizer, Moderna executives say efficacy, safety data won't be ready till well after Election Day. FDA's COVID-19 vaccine meeting on Thursday says sure to draw a big crowd.

Alex Jung of EY-Parthenon, Ernst & Young LLP, explains why therapies in new era of drug treatment are so expensive and what can be done about it.

Reporters at ProPublica, The Wall Street Journal and Science have written in-depth accounts of CDC's faded role, damaged reputation and White House interference.

The Johns Hopkins professor and new MHE editorial advisory board member lauds the effects of the Affordable Care Act but holds out for a program that “gets every human being the healthcare that every human being deserves,” in this second part of a four-part series.

Featured speaker at the 4th Annual PBMI Specialty Rx Forum on October 16 discusses theme of the meeting.

Some “don’t give a damn about their fellow man.” But in this first of four-part video series, the Johns Hopkins professor, former chief medical and scientific officer of the American Cancer Society, and MHE Editorial Advisory Board member is encouraged by diversity among protestors and the broadening of the efforts to tackle disparities of all kinds. “I think this is a long-term effort.”

Johnson & Johnson pauses trial, Pfizer wants to enroll teens, and fewer Americans are willing to be vaccinated. Here's a roundup of today's news about COVID-19 vaccines.